Tags

Type your tag names separated by a space and hit enter

Cannabis use disorders in schizophrenia: effects on cognition and symptoms.
Schizophr Res 2010; 120(1-3):95-100SR

Abstract

OBJECTIVE

Despite the controversy surrounding the possible causal link between cannabis use and the onset of schizophrenia (SZ), data seeking to elucidate the effect of cannabis use disorders (CUDs) on the clinical presentation of SZ have produced mixed results. Although several studies have suggested that CUD in patients with SZ may be associated with variation in cognitive function, clinical presentation and course of illness, the effects have been inconsistent.

METHODS

We retrospectively ascertained a large cohort (N=455) of SZ patients with either no history of a CUD (CUD-; N=280) or a history of CUD (CUD+; N=175). The groups were initially compared on key demographic variables including sex, race, age, age at onset of SZ, parental socioeconomic status, premorbid IQ, education level and global assessment of functioning. Covarying for any observed differences in demographic variables, we then compared groups on lifetime measures of psychotic symptoms as well as a brief battery of neurocognitive tests.

RESULTS

Compared to the CUD- group the CUD+ group demonstrated significantly better performance on measures of processing speed (Trail Making Tests A and B), verbal fluency (animal naming) and verbal learning and memory (California Verbal Learning Test). Moreover, the CUD+ group had better GAF scores than the CUD group.

CONCLUSIONS

Collectively, these findings suggest that SZ patients with comorbid CUD may represent a higher functioning subgroup of SZ. Future prospective studies are needed to elucidate the nature of this relationship.

Authors+Show Affiliations

Center for Translational Psychiatry, The Feinstein Institute for Medical Research, Manhasset, NY, USA. pderosse@lij.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

20483565

Citation

DeRosse, Pamela, et al. "Cannabis Use Disorders in Schizophrenia: Effects On Cognition and Symptoms." Schizophrenia Research, vol. 120, no. 1-3, 2010, pp. 95-100.
DeRosse P, Kaplan A, Burdick KE, et al. Cannabis use disorders in schizophrenia: effects on cognition and symptoms. Schizophr Res. 2010;120(1-3):95-100.
DeRosse, P., Kaplan, A., Burdick, K. E., Lencz, T., & Malhotra, A. K. (2010). Cannabis use disorders in schizophrenia: effects on cognition and symptoms. Schizophrenia Research, 120(1-3), pp. 95-100. doi:10.1016/j.schres.2010.04.007.
DeRosse P, et al. Cannabis Use Disorders in Schizophrenia: Effects On Cognition and Symptoms. Schizophr Res. 2010;120(1-3):95-100. PubMed PMID: 20483565.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabis use disorders in schizophrenia: effects on cognition and symptoms. AU - DeRosse,Pamela, AU - Kaplan,Alyson, AU - Burdick,Katherine E, AU - Lencz,Todd, AU - Malhotra,Anil K, Y1 - 2010/05/18/ PY - 2010/02/01/received PY - 2010/04/09/revised PY - 2010/04/12/accepted PY - 2010/5/21/entrez PY - 2010/5/21/pubmed PY - 2010/10/21/medline SP - 95 EP - 100 JF - Schizophrenia research JO - Schizophr. Res. VL - 120 IS - 1-3 N2 - OBJECTIVE: Despite the controversy surrounding the possible causal link between cannabis use and the onset of schizophrenia (SZ), data seeking to elucidate the effect of cannabis use disorders (CUDs) on the clinical presentation of SZ have produced mixed results. Although several studies have suggested that CUD in patients with SZ may be associated with variation in cognitive function, clinical presentation and course of illness, the effects have been inconsistent. METHODS: We retrospectively ascertained a large cohort (N=455) of SZ patients with either no history of a CUD (CUD-; N=280) or a history of CUD (CUD+; N=175). The groups were initially compared on key demographic variables including sex, race, age, age at onset of SZ, parental socioeconomic status, premorbid IQ, education level and global assessment of functioning. Covarying for any observed differences in demographic variables, we then compared groups on lifetime measures of psychotic symptoms as well as a brief battery of neurocognitive tests. RESULTS: Compared to the CUD- group the CUD+ group demonstrated significantly better performance on measures of processing speed (Trail Making Tests A and B), verbal fluency (animal naming) and verbal learning and memory (California Verbal Learning Test). Moreover, the CUD+ group had better GAF scores than the CUD group. CONCLUSIONS: Collectively, these findings suggest that SZ patients with comorbid CUD may represent a higher functioning subgroup of SZ. Future prospective studies are needed to elucidate the nature of this relationship. SN - 1573-2509 UR - https://www.unboundmedicine.com/medline/citation/20483565/Cannabis_use_disorders_in_schizophrenia:_effects_on_cognition_and_symptoms_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0920-9964(10)01260-0 DB - PRIME DP - Unbound Medicine ER -